BioSyent Announces the Availability of Tibella® (tibolone) in Canada
July 29 2020 - 3:01PM
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today
announced the Canadian launch and product availability of Tibella®
(tibolone) for short-term treatment of vasomotor symptoms due to
estrogen deficiency in postmenopausal women, more than one year
after menopause. Tibella® displays differential
tissue-specific effects which are responsible for weak estrogenic
and progestational properties, as well as some androgenic effects.
Tibella® should be prescribed only to women with intact uteri since
the medication includes progestogenic activity.
“Tibella® has a well-established safety and
efficacy profile worldwide as it has been available for over 30
years for the treatment of the symptoms of menopause. Tibella® has
been shown to reduce bothersome symptoms such as hot flushes and
sweating episodes,” stated Dr. Robert Reid MD, Gynaecologist and
Professor Emeritus, Department of Obstetrics and Gynaecology,
Queen’s University in Kingston, Ontario.
In most women, menopause occurs after the age of
45. Approximately 60% to 80% of women will experience
vasomotor symptoms of menopause. In Canada, almost 4 million women
between the ages of 45 and 59 have gone through or will soon go
through menopause. Up to 80% of women may suffer from at least one
menopausal symptom including mood swings, irritability, interrupted
sleep, or hot flushes.
Dr. Christine Derzko, Associate Professor in the
Department of Internal Medicine, Division of Endocrinology at the
University of Toronto stated, “Women have been suffering from
vasomotor symptoms for years and it is important to have more
options available for treatment. Having Tibella® available in
Canada provides us this opportunity and benefits Canadian
women.”
Tibella® shipments to Canadian wholesalers have
commenced.
“We are excited to bring this safe and effective
treatment to Canadian women who are suffering from the vasomotor
symptoms of menopause,” said René Goehrum, President and CEO of
BioSyent. Mr. Goehrum continued, “Tibella® is now available
at pharmacies for Canadian women. Tibella® is the newest addition
to BioSyent’s Women’s Health portfolio which also includes FeraMAX®
for the prevention and treatment of iron deficiency anemia and
RepaGyn® which relieves dryness and helps to promote healing
of the vaginal mucosa. We are committed to further expanding our
Canadian business with future product launches and by continuing to
assemble a broad portfolio of products that serve unmet medical
needs.”
François Fornieri, CEO of Mithra Women’s Health,
commented, “We are very proud to see our product being launched as
Tibella® in Canada by our partner BioSyent. We are delighted to
provide Canadian physicians and women with a long-awaited treatment
option to safely and effectively address menopausal symptoms.”
Tibella® is developed and manufactured by Mithra
Pharmaceuticals. Tibella® is a registered trademark of BioSyent
Pharma Inc.
References:
Tibella Product Monograph, May 2019.
https://pdf.hres.ca/dpd_pm/00051104.PDF
The Society of Obstetricians and Gynaecologists of Canada.
www.menopauseandu.ca
Canadian Menopause Society. www.sigmamenopause.com
Statistics Canada: Population by sex and age group:
2019 Census Data.
http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo10z-eng.htm
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of
patients. BioSyent supports the healthcare professionals that
treat these patients by marketing its products through its
community, hospital and international business units.
As of the date of this press release, the
Company has 12,808,170 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.Phone: 905-206-0013E-Mail: investors@biosyent.comWeb:
www.biosyent.com
This press release may contain information or
statements that are forward-looking. The contents herein
represent our judgment, as at the release date, and are subject to
risks and uncertainties that may cause actual results or outcomes
to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited
to, those associated with clinical trials, product development,
future revenue, operations, profitability and obtaining regulatory
approvals.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Biosyent (TSXV:RX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2023 to Apr 2024